Article

Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - the Croatian study.

Department of Psychiatry, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
Psychiatria Danubina (Impact Factor: 0.65). 06/2010; 22(2):231-5.
Source: PubMed

ABSTRACT Depression is prevalent in patients with type 2 diabetes and affects quality of life. The prevalence of depression in the sample of Croatian patients with diabetes is 32.2%. The main aim of the investigation was to evaluate the effect of antidepressant treatment on quality of life and metabolic control in depressed diabetic patients.
In the sample we randomized 60 diabetic outpatients with optimally controlled diabetes and with depression. The efficacy of 50 mg sertraline per day treatment was tested by the MADRAS questionnaire in a 24-week period, where the patients controlled themselves. Changes in the quality of life as the consequences of treatment of depression were tested by the QLSQ questionnaire for the quality of life follow-up.
The MADRAS scale results, measuring the changes in the degree of depression, showed substantial improvement of condition throughout the whole treatment. The first eight weeks of treatment presented statistically high significance in examinees in all the groups of chronic somatic diseases. The QLSQ scale results for measuring the quality of life showed marked improvement. Statistically significant changes occurred during the first eight weeks of treatment. Two patients withdrew their consent before starting medication and 13 dropped out later in the study. Treatment of depression with sertraline in chronic somatic patients did not induce changes in the HbA1c.
that the prevalence of depression in patients with somatic diseases is several times higher than in general population. Treatment of depression with antidepressants from the group of selective serotonin reuptake inhibitors (sertraline) causes improvement of depressive symptoms and increases the quality of life in diabetic patients. Treatment of depression has no impact upon the values control parameters in these patients.

Download full-text

Full-text

Available from: Branimir Margetić, Sep 02, 2015
2 Followers
 · 
156 Views
 · 
50 Downloads
  • Source
    • "Antidepressant treatment brings about improvement of depressive symptoms, prevents recurrences and increases the quality of life in diabetic patients. Some clinical studies show the association of antidepressant effects and improvement of glycemic control (Lustman et al. 2007, Abrahamian et al. 2009), but reduction of depressive symptoms upon antidepressive treatment was not accompanied by simultaneous improvement of glycoregulation , according to the results of other studies (Lustman et al. 1997, Georgiades et al. 2007, Filipčić et al. 2010). Patients with T2DM and concomitant depression are a subset with a worse clinical course and health outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes (T2DM) doubles the odds of comorbid depression. Depression is a strong predictor of developing T2DM. The aim of the study was to compare depressed patients with T2DM to non-depressed ones with respect to demographic, psycho-social, clinical, anthropometric and metabolic characteristics; to examine the relationship between glycemic control and depression severity in depressed patients; to estimate the risk factors of depression. A group of depressed diabetic patients comprising those with a Major depressive episode, first or repeated (ICD-10; 1992) and endocrinologist-diagnosed T2DM, duration ≥5 years on oral, insulin therapy or both (N=46) and non-depressed ones (N=44) (90 in total) of both genders (<65 years) were included in this cross-sectional study. Laboratory and non-laboratory measures were performed.. The patient Health Questionnaire (PHQ-9) and a structured interview (MINI) were used to establish diagnosis, while the Beck Depression Inventory (BDI; cut off ≥16) was used to assess the severity ofdepression. Scaling of Life Events (SLE) for self-assessment of life events and Problem in Areas in Diabetes (PAID) for self-assessment of diabetes distress were also performed. Statistically significant higher rates of psychiatric heredity, neuropathy, higher level of diabetes related distress and a greater number of life events in depressed patients compared to non-depressed ones were found. There was a statistically significant positive correlation between BDI somatic subscore and the HbA1c level (r=0.343; p=0.020). The level of diabetes related distress (OR=1.084; p=0.000), total number of life events (OR=4.528; p=0.001) and neuropathy (OR=8.699; p=0.039) were statistically significant predictors of depression using logistic regression. The results obtained showed that depression in diabetic patients was predicted by both psychological (diabetes related distress, life events) and disease-specific variables (neuropathy). The severity of self-reported somatic depressive symptoms significantly correlated with the HbA1c level in depressed diabetic patients.
    Psychiatria Danubina 03/2011; 23(1):34-44. · 0.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Comorbid depression is common in patients with type 2 diabetes mellitus and is associated with greater mortality risk and a higher incidence of diabetic complications and decreased quality of life. In an earlier pilot study, we found that treatment with the serotonin norepinephrine reuptake inhibitor antidepressant, milnacipran, significantly improved metabolic parameters in diabetic patients with comorbid depression who had an antidepressant response. We sought to replicate these results in a larger cohort (n = 135). Patients received milnacipran and metformin for 6 months and metabolic parameters and depressive symptoms were measured at baseline and after 3 and 6 months. At the end of the study, 72.6% of patients had an antidepressant response (≥50% reduction of baseline Beck Depression Inventory score). Overall, there was significant improvement in the metabolic and anthropometric parameters measured. The number of patients with glycated hemoglobin > 8% (>63.9 mmol/mol), an indicator of poor metabolic control requiring intensive therapeutic intervention, decreased from 31.9% at baseline to 11.9% during the study. As found in the pilot study, levels of total cholesterol and triglycerides were only significantly decreased in antidepressant responders. Body weight was significantly reduced in both responders and nonresponders but the effect size was significantly greater in the responder group. In contrast to the pilot study, fasting blood glucose and glycated hemoglobin were significantly decreased to a similar extent in both antidepressant-responders and nonresponders. The present study thus replicates some of the original findings. The main difference between the present and the pilot study is that in the larger cohort significant reductions in fasting blood glucose and glycated hemoglobin were found in all patients irrespective of whether or not they responded to antidepressant treatment. The present data underline the importance of diagnosis and treatment of comorbid depression in patients with type 2 diabetes mellitus with milnacipran.
    Neuropsychiatric Disease and Treatment 08/2012; 8:355-60. DOI:10.2147/NDT.S33679 · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review outlines the effect of depression on quality of life (QoL) in patients with Type 2 diabetes mellitus (T2DM). The prevalence and medical, psychological and financial burden of T2DM in the USA are briefly discussed, similar to the findings related to patients living with T2DM and depression in terms of health-related QoL. Recommendations for future research include studying mechanisms by which depression affects the QoL of T2DM patients, outlining effects of positive emotions on managing consequences of distress and depression in these patients, and developing interventions to address both depression and diabetes that minimize the treatment burden and costs for patients.
    Expert Review of Pharmacoeconomics & Outcomes Research 02/2013; 13(1):83-91. DOI:10.1586/erp.12.86 · 1.87 Impact Factor